Ignyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic lymphoma kinase (ALK) proteins for the treatment of solid tumors. Its entrectinib is in Phase II/III of clinical development. Its taladegib is a small molecule and hedgehog or smoothened antagonist.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: RXDX
- Previous Close: $8.70
- 50 Day Moving Average: $6.40
- 200 Day Moving Average: $5.98
- 52-Week Range: $41,652,000.00 - $4.15
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.54
- P/E Growth: 0.00
- Market Cap: $362.37M
- Outstanding Shares: 41,652,000
- Beta: 1.44
- Return on Equity: -90.70%
- Return on Assets: -60.50%
Companies Related to Ignyta:
- Debt-to-Equity Ratio: 0.24%
- Current Ratio: 9.27%
- Quick Ratio: 9.27%
What is Ignyta's stock symbol?
Ignyta trades on the NASDAQ under the ticker symbol "RXDX."
Where is Ignyta's stock going? Where will Ignyta's stock price be in 2017?
6 brokerages have issued 12-month price objectives for Ignyta's stock. Their predictions range from $15.00 to $20.00. On average, they expect Ignyta's share price to reach $18.00 in the next year.
When will Ignyta announce their earnings?
Ignyta is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about Ignyta stock?
Here are some recent quotes from research analysts about Ignyta stock:
According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (1/11/2017)
Jefferies Group LLC analysts commented, "ENA preclinical posters on RXDX-106 showed encouraging activity in both immuno-oncologic modulation and direct tumor targeting. These initial data support further development of ‘106 and we would look for more details at Dec 1 conference call. Incremental preclinical data of ‘105 and entrectinib were also presented." (11/30/2016)
Who owns Ignyta stock?
Ignyta's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (5.42%), Armistice Capital LLC (4.80%), Frazier Management LLC (2.28%), Artal Group S.A. (2.04%), FMR LLC (1.26%) and State Street Corp (1.02%). Company insiders that own Ignyta stock include Alexander W Casdin, City Hill Venture Partners I,, Jacob Chacko, James A Bristol, James L Freddo, Jonathan E Lim and Robert Wild.
Who sold Ignyta stock? Who is selling Ignyta stock?
Ignyta's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC.
Who bought Ignyta stock? Who is buying Ignyta stock?
Ignyta's stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Boxer Capital LLC, State Street Corp, Dimensional Fund Advisors LP, Teza Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought Ignyta stock in the last two years include Alexander W Casdin, City Hill Venture Partners I,, Jacob Chacko, James A Bristol, James L Freddo, Jonathan E Lim and Robert Wild.
How do I buy Ignyta stock?
Shares of Ignyta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ignyta stock cost?
One share of Ignyta stock can currently be purchased for approximately $8.70.